FDA Approves Ifinatamab Deruxtecan for Extensive-Stage Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression after platinum-based chemotherapy. This approval follows a Priority Review, Real-Time Oncology Review, and Project Orbis review.